Merck & Co's Arcoxia now for ankylosing spondylitis in the UK
This article was originally published in Scrip
Merck Sharp & Dohme COX-2 inhibitor Arcoxia (etoricoxib) is now being marketed in the UK to relieve the symptoms of ankylosing spondylitis (AS), following adoption of the new indication by the European Commission in September last year
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.